He discovered that chemotherapy-resistant osteosarcoma is highly sensitive to IL-15-activated allogeneic and autologous NK cells, supporting the therapeutic potential of NK cells or NK cell activators in high-grade osteosarcoma patients. Here, IL15 is linked to osteosarcoma.